BridgeBio Pharma Inc Earnings
The next earnings date for BridgeBio Pharma Inc is August 5, 2025.
They are scheduled to announce earnings after the market closes that day.
Analyst Estimates of BridgeBio Pharma Inc Earnings
What is an Earnings Date
An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.
Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.
Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.
BridgeBio Pharma Inc Earnings: Historical
More About BridgeBio Pharma Inc
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; low-dose infigratinib, a treatment option for children living with hypochondroplasia, a skeletal dysplasia closely related to achondroplasia which is in Phase 2/3. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. The company has license and collaboration agreements with the Alexion Pharma International Operations Unlimited Company, Leland Stanford Junior University and Leidos Biomedical Research, Inc., and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
“BridgeBio Pharma Inc Earnings” Can Refer to the BridgeBio Pharma Inc Earnings Date
Some people say “BridgeBio Pharma Inc earnings” as a shortform way to refer to the earnings date.
For example, someone might say, “I plan to hold my BridgeBio Pharma Inc position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.
Owning BridgeBio Pharma Inc Stock on the Earnings Date
If you own BridgeBio Pharma Inc stock (BBIO) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.
A company’s earnings typically have a big impact on its stock price, which explains why the stock price for BridgeBio Pharma Inc might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.
There is often a big audience of investors involved with trading BridgeBio Pharma Inc shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.
These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.
Owning BridgeBio Pharma Inc Options on the Earnings Date
If you own BridgeBio Pharma Inc options on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.
In addition, the extrinsic values of BridgeBio Pharma Inc options that overlap earnings dates are often higher than other days of the year. In other words, the premiums you pay to own BridgeBio Pharma Inc options are typically higher during that period. In particular, they are frequently higher immediately before earnings and on the day they’re announced.
This makes sense considering that prices are often more volatile on earnings dates for BridgeBio Pharma Inc. That potential volatility is a key factor that affects the premium cost of owning options.
Once the earnings announcement is done and the anticipated price volatility has gone down, the extrinsic values of BridgeBio Pharma Inc options often go down. This is sometimes referred to as volatility crush.
Learning More BridgeBio Pharma Inc Earnings
You can contact us any time if you would like to ask questions about BridgeBio Pharma Inc earnings or anything else related to the stock market.